Gold prices fell nearly 0.9% after U.S. October jobs data showed a much stronger-than-expected gain of 165,000 new jobs, lowering unemployment to 4.1% and pushing wages higher. This robust labor market supports expectations for another Federal Reserve interest rate hike in December, which lifted Treasury yields and the dollar, pressuring gold. Meanwhile, geopolitical tensions in the Strait of Hormuz and mixed market reactions to tech sector declines add complexity to the outlook. Investors now await upcoming inflation data to gauge the Fed's next moves amid ongoing economic resilience and global risks.
Gold prices and U.S. payrolls data provide context for market activity. For readers following U.S. stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:21 WIB: out of 150 priced US stocks, 60 rose and 85 fell. Notable movers include MRVL at USD 146.61 (+9.78%), UMC at USD 14.59 (+9.04%), and AMAT at USD 346.71 (+8.60%).
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
